Finetuning the Potency & Safety of 4-1BB Agonist Antibodies By Targeting the Membrane Proximal Region
Time: 9:00 am
day: Day One
Details:
- Unique anti-4-1BB VHH that binds to the membrane proximal domain to maintain potency and reduce toxicity risk
- CLDN18.2 x 4-1BB bispecific shows good safety and preliminary efficacy in CLDN18.2+ cancer patients
- 4-1BB bispecific platform can be further optimized with unidirectional Fc effector function towards TAAs but not 4-1BB+ cells
